124 related articles for article (PubMed ID: 23566532)
1. Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors.
Yasumoto A; Madoiwa S; Kashiwakura Y; Ishiwata A; Ohmori T; Mizukami H; Ozawa K; Sakata Y; Mimuro J
Thromb Res; 2013 May; 131(5):444-9. PubMed ID: 23566532
[TBL] [Abstract][Full Text] [Related]
2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.
Margaritis P; Arruda VR; Aljamali M; Camire RM; Schlachterman A; High KA
J Clin Invest; 2004 Apr; 113(7):1025-31. PubMed ID: 15057309
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.
Ohmori T; Ishiwata A; Kashiwakura Y; Madoiwa S; Mitomo K; Suzuki H; Hasegawa M; Mimuro J; Sakata Y
Mol Ther; 2008 Aug; 16(8):1359-65. PubMed ID: 18523449
[TBL] [Abstract][Full Text] [Related]
5. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
[TBL] [Abstract][Full Text] [Related]
6. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors.
Petersen LC; Elm T; Ezban M; Krogh TN; Karpf DM; Steinø A; Olsen EH; Sørensen BB
Thromb Haemost; 2009 May; 101(5):818-26. PubMed ID: 19404533
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
Margaritis P; Roy E; Aljamali MN; Downey HD; Giger U; Zhou S; Merricks E; Dillow A; Ezban M; Nichols TC; High KA
Blood; 2009 Apr; 113(16):3682-9. PubMed ID: 19109232
[TBL] [Abstract][Full Text] [Related]
8. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
Margaritis P
Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
10. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
[TBL] [Abstract][Full Text] [Related]
11. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
12. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
13. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
Margaritis P; Roy E; Faella A; Downey HD; Ivanciu L; Pavani G; Zhou S; Bunte RM; High KA
Blood; 2011 Apr; 117(15):3974-82. PubMed ID: 21325603
[TBL] [Abstract][Full Text] [Related]
14. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
17. Advances in gene therapy using factor VIIa in hemophilia.
Margaritis P; High KA
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S101-4. PubMed ID: 16427374
[TBL] [Abstract][Full Text] [Related]
18. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
19. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method.
Halabian R; Roudkenar MH; Esmaeili NS; Masroori N; Roushandeh AM; Najafabadi AJ
Vox Sang; 2009 May; 96(4):309-15. PubMed ID: 19175565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
